239 related articles for article (PubMed ID: 11888921)
1. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.
Ganss R; Ryschich E; Klar E; Arnold B; Hämmerling GJ
Cancer Res; 2002 Mar; 62(5):1462-70. PubMed ID: 11888921
[TBL] [Abstract][Full Text] [Related]
2. Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells.
Mukai S; Kagamu H; Shu S; Plautz GE
Cell Immunol; 1999 Mar; 192(2):122-32. PubMed ID: 10087180
[TBL] [Abstract][Full Text] [Related]
3. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression.
Ogawa M; Umehara K; Yu WG; Uekusa Y; Nakajima C; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1999 Apr; 59(7):1531-8. PubMed ID: 10197625
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.
Ganss R; Hanahan D
Cancer Res; 1998 Oct; 58(20):4673-81. PubMed ID: 9788621
[TBL] [Abstract][Full Text] [Related]
5. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
Jorritsma A; Bins AD; Schumacher TN; Haanen JB
Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
[TBL] [Abstract][Full Text] [Related]
6. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.
Wang LX; Shu S; Plautz GE
Cancer Res; 2005 Oct; 65(20):9547-54. PubMed ID: 16230420
[TBL] [Abstract][Full Text] [Related]
7. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
[TBL] [Abstract][Full Text] [Related]
8. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
[TBL] [Abstract][Full Text] [Related]
9. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.
Park MY; Kim CH; Sohn HJ; Oh ST; Kim SG; Kim TG
Vaccine; 2007 Oct; 25(42):7322-30. PubMed ID: 17889413
[TBL] [Abstract][Full Text] [Related]
10. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
11. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
12. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
13. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Qin Z; Schwartzkopff J; Pradera F; Kammertoens T; Seliger B; Pircher H; Blankenstein T
Cancer Res; 2003 Jul; 63(14):4095-100. PubMed ID: 12874012
[TBL] [Abstract][Full Text] [Related]
14. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
15. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
16. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity.
Yang X; Chu Y; Wang Y; Zhang R; Xiong S
J Leukoc Biol; 2006 Dec; 80(6):1434-44. PubMed ID: 16980511
[TBL] [Abstract][Full Text] [Related]
17. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
[TBL] [Abstract][Full Text] [Related]
18. IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1.
Jaruga B; Hong F; Kim WH; Gao B
Am J Physiol Gastrointest Liver Physiol; 2004 Nov; 287(5):G1044-52. PubMed ID: 15246962
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
Nishimura F; Dusak JE; Eguchi J; Zhu X; Gambotto A; Storkus WJ; Okada H
Cancer Res; 2006 Apr; 66(8):4478-87. PubMed ID: 16618775
[TBL] [Abstract][Full Text] [Related]
20. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
